Tempus Q1 2025: Unpacking Contradictions in Revenue Guidance, Insights Growth, and Market Dynamics
Earnings DecryptWednesday, May 7, 2025 7:28 pm ET

Revenue guidance and growth expectations, Insights business growth and market position,
Strong Financial Performance and Revenue Growth:
- Tempus AI, Inc. reported record revenue of $255.7 million for Q1 2025, up 75.4% year-over-year.
- The growth was driven by double-digit increases in Genomics and Oncology testing, as well as robust growth in the Data and Services segment.
Oncology Testing and Genomics Growth:
- Oncology testing revenue grew by 31% year-over-year, with a 20% increase in volume, and Genomics revenue reached $193.8 million, indicating 89% year-over-year growth.
- This growth was attributed to strong demand for Tempus's diagnostic and testing services, particularly in oncology.
Data and Services Expansion:
- Revenue from Data and Services totaled $61.9 million, representing a 43% year-over-year increase, with Insights or data licensing business growing 58%.
- The expansion in this segment was supported by the signing of new data licensing agreements, such as the $200 million deal with AstraZeneca and Pathos.
Hereditary Testing Performance:
- The legacy Ambry Genetics business contributed $63.5 million in revenue, growing its units by 23%.
- The strong performance was driven by increased demand for hereditary testing services and the integration of Ambry's capabilities into Tempus's offerings.
Adjusted EBITDA Improvement:
- Tempus AI reported an improvement in adjusted EBITDA, with a negative $16.2 million in Q1 2025, compared to negative $43.9 million in Q1 2024, indicating a $27.8 million year-over-year improvement.
- This improvement was attributed to better cost management and operating leverage, despite significant investments in growth initiatives.
Strong Financial Performance and Revenue Growth:
- Tempus AI, Inc. reported record revenue of $255.7 million for Q1 2025, up 75.4% year-over-year.
- The growth was driven by double-digit increases in Genomics and Oncology testing, as well as robust growth in the Data and Services segment.
Oncology Testing and Genomics Growth:
- Oncology testing revenue grew by 31% year-over-year, with a 20% increase in volume, and Genomics revenue reached $193.8 million, indicating 89% year-over-year growth.
- This growth was attributed to strong demand for Tempus's diagnostic and testing services, particularly in oncology.
Data and Services Expansion:
- Revenue from Data and Services totaled $61.9 million, representing a 43% year-over-year increase, with Insights or data licensing business growing 58%.
- The expansion in this segment was supported by the signing of new data licensing agreements, such as the $200 million deal with AstraZeneca and Pathos.
Hereditary Testing Performance:
- The legacy Ambry Genetics business contributed $63.5 million in revenue, growing its units by 23%.
- The strong performance was driven by increased demand for hereditary testing services and the integration of Ambry's capabilities into Tempus's offerings.
Adjusted EBITDA Improvement:
- Tempus AI reported an improvement in adjusted EBITDA, with a negative $16.2 million in Q1 2025, compared to negative $43.9 million in Q1 2024, indicating a $27.8 million year-over-year improvement.
- This improvement was attributed to better cost management and operating leverage, despite significant investments in growth initiatives.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet